FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.

Related Articles

Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Idexx Laboratories, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $612 from $620, based on 37.3x our 2027 EPS estimate, below IDXX's historical forward P/E averages. We slightly raise our 2026 EPS view to $14.70 from 14.67. We keep our 2027 view at $16.42. IDXX reported a solid Q1, exceeding expectations, with revenue of $1.141B (+11% Y/Y organic) due to strong performance in its Companion Animal Group Diagnostics recurring revenue. However, we see IDXX facing risks in the near term stemming from macroeconomic pressures on consumers that are causing a decline in discretionary wellness-related veterinary visits. This trend poses a financial risk, as IDXX full-year guidance assumes a 1.5% decline in U.S. clinical visits; thus, a further worsening of the economic environment could lead to steeper declines and challenge revenue targets. Additionally, IDXX flagged a minor supply chain disruption in the Middle East, which, while contained, underscores the potential for broader operational risks within global business activities.

$IDXX
Sectors

Sector Update: Energy

Energy stocks were higher Tuesday afternoon, with the NYSE Energy Sector Index rising 0.5% and the State Street Energy Select Sector SPDR ETF (XLE) up 0.3%.The Philadelphia Oil Service Sector Index was decreasing 0.4%, and the Dow Jones US Utilities Index was adding 0.8%.Front-month West Texas Intermediate crude oil was declining 4.3% to $101.80 a barrel, and the global benchmark Brent crude contract was dropping 3.9% to $110.03 a barrel. Henry Hub natural gas futures fell 2.5% to $2.80 per 1 million BTU.In corporate news, Marathon Petroleum (MPC) shares gained 1.9% after its Q1 adjusted earnings and revenue rose year on year and beat analysts' estimates.

$MPC
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Ferrari N.v.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $40 to $350, based on a 2027 P/E of 28.5x, a justified discount to RACE's 10-year average forward P/E multiple of 40.6x. We maintain our adjusted EPS estimates of EUR9.70 for 2026 and EUR10.50 for 2027. Following Ferrari's disappointing Q1 results, we are lowering our price target and maintaining our Hold rating. The company's Q1 earnings shortfall was driven by weaker-than-expected margins and it maintained full-year guidance. The miss was uncharacteristic for a company with one of the strongest earnings track records in the industry. In our view, RACE's lack of vehicle sales growth (-4.4% in Q1) continues to present a challenge to margins given the high fixed cost nature of auto manufacturing. Moreover, we continue to have doubts longer-term regarding its planned 2030 portfolio pivot into electric and hybrid vehicles, and view the stock's risk/reward potential as balanced at current levels.

$RACE